Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have a long-term (chronic) hepatitis C infection, liver scarring (fibrosis), severe liver scarring (cirrhosis), or liver cancer linked to hepatitis C
- People who are able to understand and are willing to sign a consent form agreeing to take part in the study
- People who are able to answer the questions in the enrollment questionnaire
Who may not be able to join:
- People who are currently receiving treatment for another type of cancer
- People who have a weakened immune system, whether from birth, from HIV infection, from having had an organ transplant, or from taking medications that suppress the immune system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Valli De Re, PhD, Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
Phone: +39 0434 659672
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference in antibody profile between subjects with and without chronic HCV infection; Difference in antibody profile between subjects with chronic HCV infection receiving or not receiving DAA therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.